<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04933825</url>
  </required_header>
  <id_info>
    <org_study_id>EDI002</org_study_id>
    <nct_id>NCT04933825</nct_id>
  </id_info>
  <brief_title>A Study of ET-02 in Patients With Relapsed or Refractory B-cell Malignancy(NHL/ALL)</brief_title>
  <official_title>An Exploratory,Open-label,and Single Center Study to Evaluate the Safety and Efficacy of ET-02 in Patients With Relapsed or Refractory B-cell Malignancies(NHL/ALL).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EdiGene (GuangZhou) Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The First Affiliated Hospital of Henan University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>EdiGene (GuangZhou) Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of CD19-UCART in patients&#xD;
      with r/r B-cell hematological malignancies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 20, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>up to 2 years after lymphodepleting chemotherapy</time_frame>
    <description>Adverse events assessed according to NCI-CTCAE v5.0 criteria</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Relapsed or Refractory B-cell Malignancy(NHL/ALL)</condition>
  <arm_group>
    <arm_group_label>Four escalating dose-levels of ET-02 will be evaluated using a &quot;3+3&quot; design.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ET-02</intervention_name>
    <description>A conditioning therapy with cyclophosphamide and fludarabine will be conducted before ET-02 injection.</description>
    <arm_group_label>Four escalating dose-levels of ET-02 will be evaluated using a &quot;3+3&quot; design.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients volunteer to participate in the study and sign the ICF;&#xD;
&#xD;
          2. Male or female aged≥18 years old；&#xD;
&#xD;
          3. Patient with relapsed or refractory CD19 positive B-ALL orNHL，as evidenced by 2 or&#xD;
             more lines of prior therapy ;&#xD;
&#xD;
          4. Estimated life expectancy≥12 weeks ;&#xD;
&#xD;
          5. ECOG performance status ≤1;&#xD;
&#xD;
          6. Adequate organ function.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with graft-versus-host disease (GVHD) or requiring immunosuppressive therapy；&#xD;
&#xD;
          2. History of central nervous system (CNS) involvement by malignancy；&#xD;
&#xD;
          3. Women who are pregnant or breastfeeding；&#xD;
&#xD;
          4. Any situations that may increase the risk of patients or interfere with the results of&#xD;
             study，which judged by investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ling Qin, Ph.D</last_name>
    <phone>+8613838837729</phone>
    <email>zzqq777@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>•The First Affiliated Hospital of Henan University of Science and Technology</name>
      <address>
        <city>Luoyang</city>
        <state>Henan</state>
        <zip>471003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 9, 2021</study_first_submitted>
  <study_first_submitted_qc>June 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2021</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

